Cyril P. Clarke

The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial

John G.F. Cleland, John R. Teerlink, Roxy Senior et al. · The Lancet · 2011 · 329 citations

Cardiomyopathy, Heart Failure, Omecamtiv Mecarbil +10

Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study

John R. Teerlink, Cyril P. Clarke, Khalil G. Saikali et al. · The Lancet · 2011 · 260 citations

Cardiac Muscle, Cardiomyopathy, Omecamtiv Mecarbil +12

Evaluation of the analgesic efficacy and psychoactive effects of <scp>AZD</scp>1940, a novel peripherally acting cannabinoid agonist, in human capsaicin‐induced pain and hyperalgesia

Jarkko Kalliomäki, Peter Annas, Karin Huizar et al. · Clinical and Experimental Pharmacology and Physiology · 2013 · 58 citations

Brain Serotonin Transporter Occupancy by Oral Sibutramine Dosed to Steady State: A PET Study Using 11C-DASB in Healthy Humans

Peter S. Talbot, Stefan Bradley, Cyril P. Clarke et al. · Neuropsychopharmacology · 2009 · 28 citations · Full text

Steady State, Psychiatry, Neurophysiology +9

Comparison of a novel fast-dissolving acetaminophen tablet formulation (FD-APAP) and standard acetaminophen tablets using gamma scintigraphy and pharmacokinetic studies

Clive Wilson, Cyril P. Clarke, Yan Yan L. Starkey et al. · Drug Development and Industrial Pharmacy · 2011 · 24 citations · Full text